Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
Status:
Not yet recruiting
Trial end date:
2026-09-20
Target enrollment:
Participant gender:
Summary
This research study evaluates the effects of an FDA-approved medication Gabapentin in
individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be
assigned to take either Gabapentin or a matched placebo. Study medication will be taken for
17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed.
Questionnaires and clinical interview measures will be completed at study visits along with
consistent assessment of potential side effects from study medication.